Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Environ Microbiol ; 10(3): 789-98, 2008 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-18237311

RESUMEN

A role for the intestinal microbiota is routinely cited as a potential aetiological factor in colorectal cancer initiation and progression. As the majority of bacteria in the gut are refractory to culture we investigated this ecosystem in subjects with colorectal cancer and with adenomatous polyposis who are at high risk of developing colorectal cancer, using culture-independent methods. Twenty colorectal cancer and 20 polypectomized volunteers were chosen for this analysis. An exploration of the diversity and temporal stability of the dominant bacteria and several bacterial subgroups was undertaken using 16S rRNA gene denaturing gradient gel electrophoresis and ribosomal intergenic spacer analysis (RISA). Metabonomic analysis of the distal gut microbiota's environment was also undertaken. A significantly reduced temporal stability and increased diversity for the microbiota of subjects with colorectal cancer and polyposis was evident. A significantly increased diversity of the Clostridium leptum and C. coccoides subgroups was also noted for both disease groups. A clear division in the metabonome was observed for the colorectal cancer and polypectomized subjects compared with control volunteers. The intestinal microbiota and their metabolites are significantly altered in both colorectal cancer and polypectomized subjects compared with controls.


Asunto(s)
Poliposis Adenomatosa del Colon/microbiología , Neoplasias Colorrectales/microbiología , ADN Espaciador Ribosómico/análisis , Intestinos/microbiología , ARN Ribosómico 16S/análisis , Biodiversidad , Clostridium/clasificación , Clostridium/genética , ADN Bacteriano/análisis , ADN Bacteriano/genética , Electroforesis en Gel de Poliacrilamida , Femenino , Tracto Gastrointestinal , Humanos , Masculino , ARN Ribosómico 16S/genética
2.
Nutr Cancer ; 57(2): 158-67, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-17571949

RESUMEN

The assessment of cellular effects by the aqueous phase of human feces (fecal water, FW) is a useful biomarker approach to study cancer risks and protective activities of food. In order to refine and develop the biomarker, different protocols of preparing FW were compared. Fecal waters were prepared by 3 methods: (A) direct centrifugation; (B) extraction of feces in PBS before centrifugation; and (C) centrifugation of lyophilized and reconstituted feces. Genotoxicity was determined in colon cells using the Comet assay. Selected samples were investigated for additional parameters related to carcinogenesis. Two of 7 FWs obtained by methods A and B were similarly genotoxic. Method B, however, yielded higher volumes of FW, allowing sterile filtration for long-term culture experiments. Four of 7 samples were non-genotoxic when prepared according to all 3 methods. FW from lyophilized feces and from fresh samples were equally genotoxic. FWs modulated cytotoxicity, paracellular permeability, and invasion, independent of their genotoxicity. All 3 methods of FW preparation can be used to assess genotoxicity. The higher volumes of FW obtained by preparation method B greatly enhance the perspectives of measuring different types of biological parameters and using these to disclose activities related to cancer development.


Asunto(s)
Técnicas de Laboratorio Clínico/normas , Daño del ADN , Heces/química , Animales , Biomarcadores , Neoplasias del Colon/epidemiología , Ensayo Cometa , Células HT29 , Humanos , Neoplasias/epidemiología , Medición de Riesgo , Agua
3.
Br J Nutr ; 97(4): 676-84, 2007 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-17349080

RESUMEN

Probiotics (PRO) modulate immunity in humans, while the effect of prebiotics (PRE) and synbiotics (SYN) on the human immune system are not well studied yet. The objective of this study was to investigate whether daily intake of a SYN modulates immune functions. In a randomised double-blind, placebo-controlled trial, thirty-four colon cancer patients who had undergone 'curative resection' and forty polypectomised patients participated. Subjects of the SYN group daily received encapsulated bacteria (1 x 10(10) colony-forming units of Lactobacillus rhamnosus GG (LGG) and 1 x 10(10) colony-forming units of Bifidobacterium lactis Bb12 (Bb12)) and 10 g of inulin enriched with oligofructose. Controls received encapsulated maltodextrin and 10 g of maltodextrin. Prior to intervention (T1), and 6 (T2) and 12 weeks after the start of the intervention (T3), phagocytic and respiratory burst activity of neutrophils and monocytes, lytic activity of natural killer cells and production of interleukin (IL)-2, IL-10 and IL-12, as well as tumour necrosis factor-alpha and interferon-gamma (IFN-gamma) by activated peripheral blood mononuclear cells (PBMC) were measured. In faeces, the concentrations of transforming growth factor-beta1 and prostaglandin E2 were measured. IL-2 secretion by activated PBMC from the polyp group increased significantly between T1 or T2 and T3 (P < 0.05). In the cancer group, SYN treatment resulted in an increased capacity of PBMC to produce IFN-gamma at T3 (P < 0.05). Other immunity-related parameters were not affected by SYN treatment, neither in the cancer nor in the polyp group. In conclusion, supplementation with this SYN has minor stimulatory effects on the systemic immune system of the two study groups. Further studies in humans should aim to focus on the gut-associated immune system.


Asunto(s)
Bifidobacterium , Neoplasias del Colon/inmunología , Inulina/inmunología , Lacticaseibacillus rhamnosus , Probióticos , Anciano , Células Cultivadas , Neoplasias del Colon/cirugía , Pólipos del Colon/cirugía , Citocinas/biosíntesis , Citotoxicidad Inmunológica , Método Doble Ciego , Femenino , Humanos , Células Asesinas Naturales/inmunología , Masculino , Persona de Mediana Edad , Oligosacáridos , Fagocitosis , Estallido Respiratorio
4.
Am J Clin Nutr ; 85(2): 488-96, 2007 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-17284748

RESUMEN

BACKGROUND: Animal studies suggest that prebiotics and probiotics exert protective effects against tumor development in the colon, but human data supporting this suggestion are weak. OBJECTIVE: The objective was to verify whether the prebiotic concept (selective interaction with colonic flora of nondigested carbohydrates) as induced by a synbiotic preparation-oligofructose-enriched inulin (SYN1) + Lactobacillus rhamnosus GG (LGG) and Bifidobacterium lactis Bb12 (BB12)-is able to reduce the risk of colon cancer in humans. DESIGN: The 12-wk randomized, double-blind, placebo-controlled trial of a synbiotic food composed of the prebiotic SYN1 and probiotics LGG and BB12 was conducted in 37 colon cancer patients and 43 polypectomized patients. Fecal and blood samples were obtained before, during, and after the intervention, and colorectal biopsy samples were obtained before and after the intervention. The effect of synbiotic consumption on a battery of intermediate bio-markers for colon cancer was examined. RESULTS: Synbiotic intervention resulted in significant changes in fecal flora: Bifidobacterium and Lactobacillus increased and Clostridium perfringens decreased. The intervention significantly reduced colorectal proliferation and the capacity of fecal water to induce necrosis in colonic cells and improve epithelial barrier function in polypectomized patients. Genotoxicity assays of colonic biopsy samples indicated a decreased exposure to genotoxins in polypectomized patients at the end of the intervention period. Synbiotic consumption prevented an increased secretion of interleukin 2 by peripheral blood mononuclear cells in the polypectomized patients and increased the production of interferon gamma in the cancer patients. CONCLUSIONS: Several colorectal cancer biomarkers can be altered favorably by synbiotic intervention.


Asunto(s)
Bifidobacterium/fisiología , Neoplasias del Colon/tratamiento farmacológico , Pólipos del Colon/cirugía , Inulina/metabolismo , Lactobacillus/fisiología , Anciano , Neoplasias del Colon/sangre , Pólipos del Colon/tratamiento farmacológico , Suplementos Dietéticos , Método Doble Ciego , Heces/química , Heces/microbiología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Factores de Riesgo , Agua
5.
Br J Nutr ; 93 Suppl 1: S91-8, 2005 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-15877901

RESUMEN

Experimental evidence on the anticancer properties of dietary prebiotics such as chicory inulin and oligofructose and dietary probiotics has accumulated in recent years. Various experimental models ranging from chemoprevention studies, tumour implantation models to genetically modified mice models, etc. have systematically shown the protective effects of these food ingredients. In some studies it appeared that synbiotics (combination of pre- and probiotics) exerted synergistic activity against processes of carcinogenesis. The logical next step in research was to find out if these observations also would be valid for human volunteers. This was the principal goal of the EU-sponsored SYNCAN project (QLK1-1999-346) which involved the integration of an in vitro study to select the most suitable synbiotic preparation, the application of this synbiotic in an in vivo rat model of chemically induced colon cancer, and, as the heart of the project, the investigation of the synbiotic effects in a human intervention study. The in vitro tests consisted of fermentation studies where the interaction of pre- and probiotics was studied. Cell-free supernatants were generated from various synbiotic combinations fermented by faecal slurry, which were then used to optimise a series of bioassays. In the rat study the anticarcinogenic effect of prebiotics and synbiotics but not of probiotics was demonstrated. Using tissue samples generated in this model, attempts were made to gain a better insight into the mechanisms underlying cancer development. The human intervention study consisted of two groups of volunteers. One group was composed of people at high risk (polypectomised subjects) for colon cancer and the other of volunteers (colon cancer subjects) who had previously undergone 'curative resection' for colon cancer but were not currently receiving treatment. The present paper describes the experimental design of the SYNCAN study, and demonstrates a functional effect of the synbiotic preparation (probiotic survival during gastrointestinal transit and modification of the intestinal flora). Detailed experimental outcome of the human intervention study will be reported elsewhere.


Asunto(s)
Neoplasias del Colon/prevención & control , Fibras de la Dieta/administración & dosificación , Inulina/administración & dosificación , Oligosacáridos/administración & dosificación , Probióticos/administración & dosificación , Animales , Bifidobacterium , Terapia Combinada , Humanos , Lactobacillus , Modelos Animales , Ensayos Clínicos Controlados Aleatorios como Asunto , Ratas , Proyectos de Investigación , Riesgo
6.
Carcinogenesis ; 23(11): 1953-60, 2002 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-12419846

RESUMEN

Prebiotics such as fructans, and probiotics such as Lactobacilli or Bifidobacteria, or a combination of prebiotics and probiotics (synbiotics) are thought to be protective against colon cancer. Therefore, we studied whether the prebiotic inulin enriched with oligofructose (Raftilose-Synergy1, briefly, Synergy1, 10% of the diet), probiotics [Bifidobacterium lactis (Bb12) and Lactobacillus rhamnosus (LGG), each at 5x10(8) c.f.u./g diet] or synbiotics (a combination of the two) protect rats against azoxymethane (AOM)-induced colon cancer. Male F344 rats were divided into: Controls; PRE, which were fed a diet containing Synergy1; PRO, fed a diet containing LGG and Bb12; PREPRO, fed a diet containing Synergy1, LGG and BB12. Ten days after beginning the diets, rats were treated with AOM (15 mg/kg s.c. two times); dietary treatments were continued for the entire experiment. Thirty-one weeks after AOM, rats treated with Synergy1 (PRE and PREPRO groups) had a significantly lower (P < 0.001) number of tumours (adenomas and cancers) than rats without Synergy1 (colorectal tumours/rat were 1.9 +/- 1.7, 1.1 +/- 1.1, 2.2 +/- 1.4 and 0.9 +/- 1.2 in Controls, PRE, PRO and PREPRO groups, respectively, means +/- SD). A slight, not significant effect of probiotics in reducing malignant tumours was also observed (P = 0.079). Caecal short-chain fatty acids (SCFA) were higher (P < 0.001) in the groups treated with Synergy1. Apoptosis was increased in the normal mucosa of the PRO group, while no variation was observed in the tumours. Colonic proliferation was lower in the PRE group as compared with Controls. Glutathione S-transferase placental enzyme pi type expression, and to a lesser extent, inducible NO synthase were depressed in the tumours from rats in the PRE and PREPRO groups. Cycloxygenase-2 expression was increased in the tumours of control rats but not in those from PRE, PRO or PREPRO rats. In conclusion, prebiotic administration in the diet decreases AOM-induced carcinogenesis in rats.


Asunto(s)
Adenocarcinoma/prevención & control , Adenoma/prevención & control , Antineoplásicos Fitogénicos/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Bifidobacterium/fisiología , Neoplasias del Colon/prevención & control , Inulina/uso terapéutico , Lactobacillus/fisiología , Oligosacáridos/uso terapéutico , Probióticos/uso terapéutico , Adenocarcinoma/inducido químicamente , Adenocarcinoma/enzimología , Adenoma/inducido químicamente , Adenoma/enzimología , Animales , Antineoplásicos Fitogénicos/administración & dosificación , Antineoplásicos Fitogénicos/farmacología , Apoptosis/efectos de los fármacos , Azoximetano/toxicidad , Carcinógenos/toxicidad , Ciego , División Celular/efectos de los fármacos , Neoplasias del Colon/inducido químicamente , Neoplasias del Colon/enzimología , Ciclooxigenasa 2 , Dieta , Ensayos de Selección de Medicamentos Antitumorales , Sinergismo Farmacológico , Inducción Enzimática/efectos de los fármacos , Ácidos Grasos Volátiles/metabolismo , Contenido Digestivo , Gutatión-S-Transferasa pi , Glutatión Transferasa/metabolismo , Mucosa Intestinal/efectos de los fármacos , Mucosa Intestinal/enzimología , Inulina/administración & dosificación , Inulina/farmacología , Isoenzimas/metabolismo , Masculino , Proteínas de Neoplasias/metabolismo , Oligosacáridos/administración & dosificación , Oligosacáridos/farmacología , Prostaglandina-Endoperóxido Sintasas/metabolismo , Ratas , Ratas Endogámicas F344
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA